Showing 141 - 160 results of 9,783 for search '(((( 50 nn decrease ) OR ( 50 ((ng decrease) OR (we decrease)) ))) OR ( 50 n decrease ))', query time: 0.80s Refine Results
  1. 141
  2. 142

    Identification, Synthesis, and Biological Evaluations of Potent Inhibitors Targeting Type I Protein Arginine Methyltransferases by Xiao Li (107004)

    Published 2022
    “…CARM1 (coactivator-associated arginine methyltransferase 1), which belongs to type I PRMTs (protein arginine methyltransferases), is a potential therapeutic target for treatment of multiple cancers. In this study, we first identified several hit compounds against CARM1 by structure-based virtual screening (IC<sub>50</sub> = 35.51 ± 6.68 to 68.70 ± 8.12 μM) and then carried out chemical structural optimizations, leading to six compounds with significantly improved activities targeting CARM1 (IC<sub>50</sub> = 18 ± 2 to 107 ± 6 nM). …”
  3. 143

    Variable included in analysis. by Molebatsi Moholola (20513371)

    Published 2025
    “…</p><p>Results</p><p>Our final study sample consisted of 3 256 clients, half of which received case management (N = 1 628), 1084 (33%) with a first VL in study of 50–399 copies/ml, 404 (12%) 400–999 copies/ml and 1768 (54%) >1000 copies/ml. …”
  4. 144

    Full dataset of the study. by Molebatsi Moholola (20513371)

    Published 2025
    “…</p><p>Results</p><p>Our final study sample consisted of 3 256 clients, half of which received case management (N = 1 628), 1084 (33%) with a first VL in study of 50–399 copies/ml, 404 (12%) 400–999 copies/ml and 1768 (54%) >1000 copies/ml. …”
  5. 145
  6. 146
  7. 147
  8. 148
  9. 149
  10. 150
  11. 151
  12. 152
  13. 153
  14. 154
  15. 155
  16. 156

    Data Sheet 1_Reduced hemolytic complement activity in the classical pathway (CH50) is a risk factor for poor clinical outcomes of patients with infections: a retrospective analysis... by Hiroyuki Koami (3878434)

    Published 2025
    “…We divided the patients into three groups based on the normal CH50 range: Low CH50 (< 25 U/mL; n=168), Normal CH50 (25 ≤, < 48 U/mL; n=1273), and High CH50 (48 ≤ U/mL; n=1285).…”
  17. 157

    Top 50 results of a commercial kinase screen using [γ<sup>33</sup>]-ATP and human obscurin SH3-DH as substrates. by Daniel Koch (388049)

    Published 2023
    “…While MST2 addition resulted in strong and saturable phosphorylation, TBK1 led to much lower phosphorylation levels and CaMK4 addition led to an intermediate phosphorylation level exhibiting a biphasic behaviour with phosphorylation levels decreasing at higher substrate concentrations. Since MST2 showed the highest phosphorylation levels of obscurin SH3-DH, we focused on MST2 phosphorylation in all further experiments. …”
  18. 158
  19. 159
  20. 160